Answers are grounded in this paper and cite their sources.
AXL, a member of the TAM (TYRO3, AXL, and MERTK) receptor tyrosine kinase family, has emerged as a high-priority therapeutic target in oncology. Unlike canonical oncogenic kinase drivers, AXL activation is rarely attributable to direct genetic alterations but instead arises through adaptive, non-genetic mechanisms including hypoxia, inflammation, epithelial-to-mesenchymal transition, and therapeutic selection pressure. In this review, we synthesize the current understanding of AXL biology and the translational opportunities for AXL inhibition across multiple malignancies, with a focus on glioblastoma. We explore the expanding landscape of AXL-directed therapeutics, discuss the rationale for combinatorial strategies, and highlight emerging areas of AXL regulation including the AXL-ferroptosis axis. The current understanding of AXL suggests it functions not as a bystander but as an active mediator of tumor adaptation. Successful targeting of AXL has the potential to simultaneously suppress cancer cell survival, angiogenesis, and epithelial-to-mesenchymal transition while reinvigorating antitumor immunity.
No takes yet. Share an insight, caveat, or question.
Hoffman et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: